Inhibition of Human Pancreatic Tumor Growth by Cytokine-Induced Killer Cells in Nude Mouse Xenograft Model.
- Author:
Ji Sung KIM
1
;
Yun Soo PARK
;
Ju Young KIM
;
Yong Guk KIM
;
Yeon Jin KIM
;
Hong Kyung LEE
;
Hyung Sook KIM
;
Jin Tae HONG
;
Youngsoo KIM
;
Sang Bae HAN
Author Information
- Publication Type:In Vitro ; Original Article
- Keywords: Pancreatic cancer; Adoptive immunotherapy; Cytokine-induced killer cells
- MeSH: Animals; Cytokine-Induced Killer Cells; Humans; Immunotherapy, Adoptive; Mice; Mice, Nude; Pancreatic Neoplasms; Transplantation, Heterologous
- From:Immune Network 2012;12(6):247-252
- CountryRepublic of Korea
- Language:English
- Abstract: Pancreatic cancer is the fourth commonest cause of cancer-related deaths in the world. However, no adequate therapy for pancreatic cancer has yet been found. In this study, the antitumor activity of cytokine-induced killer (CIK) cells against the human pancreatic cancer was evaluated in vitro and in vivo. Human peripheral blood mononuclear cells were cultured with IL-2-containing medium in anti-CD3 for 14 days. The resulting populations of CIK cells comprised 94% CD3+, 4% CD3-CD56+, 41% CD3+CD56+, 11% CD4+, and 73% CD8+. This heterogeneous cell population was called cytokine-induced killer (CIK) cells. At an effector-target cell ratio of 100:1, CIK cells destroyed 51% of AsPC-1 human pancreatic cancer cells, as measured by the 51Cr-release assay. In addition, CIK cells at doses of 3 and 10 million cells per mouse inhibited 42% and 70% of AsPC-1 tumor growth in nude mouse xenograft assays, respectively. This study suggests that CIK cells may be used as an adoptive immunotherapy for pancreatic cancer patients.
